



Amarantus Therapeutics

Quarterly Newsletter – Q1/2010

CEO CORNER



The past few months have been busy and very productive for Amaranus Therapeutics as the Company has achieved a number of significant scientific and business milestones. As we build upon this momentum moving into 2010, we are fueled by a strong team, clinical support, and the unwavering belief that our novel, high-potential drug candidate [AMRS001](#), discovered from our proprietary [PhenoGuard Drug Discovery Platform](#), will prove to address the apoptotic pathway associated with a wide range of diseases, including Parkinson's Disease, Ischemic Heart Disease as well as Organ Transplantation, Traumatic Brain Injury and Alzheimer's Disease.

We will continue to update you each quarter of the New Year on our progress. We hope to see you at one of the many events Amaranus Therapeutics will attend in the coming year. Please [contact us](#) for more information about our program.

[Click here view my interview at the OneMed Forum 2010 Emerging Company Finance Conference.](#)

All the best,

Martin D. Cleary
Chairman & CEO
Amarantus Therapeutics, Inc.

COMPANY NEWS

PARKINSON'S IS FIRST TARGET OF AMARANTUS PROTEIN

Silicon Valley / San Jose Business Journal

Amarantus Therapeutics Inc. has developed a protein that it says has significant potential for treatment of devastating human disorders. The protein known as MANF is designed to help reverse the damage from cell death. Its first application is in the treatment of the 1.5 million Americans diagnosed with Parkinson's disease. The second application addresses ischemic heart disease — caused by a decrease in flow of blood to the heart — which affects more than 15 million people in the United States. Other potential applications include traumatic brain injury and organ transplantation. MANF is the first of what the company believes will be a number of proteins it plans to discover and patent using a proprietary cell line technology called "PhenoGuard."

AMARANTUS EXPANDS BOARD OF DIRECTORS, ADDS CORPORATE SECRETARY

Company Press Release

In January, Amarantus appointed Vern Norviel, J.D. to the position of Corporate Secretary. Mr. Norviel is a partner at Wilson Sonsini Goodrich & Rosati, where he leads the firm's patents and innovation counseling practice. Kenneth L. Coleman, Chairman of Accelrys, Inc., a leading software provider to the biotechnology industry and Gene Mancino, a founding partner in Mancino Burfield Edgerton LLP, a life sciences executive search firm, also joined the Amarantus Board of Directors.

KEY ADDITIONS TO AMARANTUS SCIENTIFIC ADVISORY BOARD

Company Press Release

In December, Amarantus appointed two new members to its Scientific Advisory Board. Dr. Eugene Johnson, Ph.D. Professor, Department of Developmental Biology at Washington University School of Medicine, and Dr. Greg Gerhardt, Ph.D., Professor of Anatomy and Neurobiology, Neurology, and Psychiatry, and Director, Morris K. Udall Parkinson's Disease Research Center of Excellence at the University of Kentucky, joined the panel.

CNS PROTEIN THERAPEUTICS CHANGES NAME TO AMARANTUS THERAPEUTICS, APPOINTS NEW CEO MARTIN D. CLEARY

Company Press Release

In October, CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, completed a corporate name change to Amarantus Therapeutics, Inc. ("Amarantus") and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chairman & CEO. Mr. Cleary succeeded Co-founder, Gerald E. Commissiong, who has continued with the Company as Chief Business Officer.

SCIENTIFIC PUBLICATIONS

INDEPENDENT PEER-REVIEWED PUBLICATIONS IDENTIFY MULTIPLE APOPTOSIS-RELATED INDICATIONS FOR AMRS001

In 2009, several peer-review scientific publications have identified multiple apoptosis-related indications for AMRS001, a highly potent, neurotrophic factor also known as MANF. Coming after other selective neurotrophic factors such as GDNF, Neurturin, NGF, and others, AMRS001's discovery protocols were designed to identify a molecule that would be highly selective for dopamine producing neurons of the Substantia Nigra. However, the peer-reviewed data on AMRS001 emerging in the scientific literature has far exceeded our expectations in that not only is AMRS001 protective for dopamine producing neurons, it also acts at a very basic cellular level to inhibit apoptosis. While the clinical efficacy and benefit of neurotrophic factors has been in doubt, AMRS001 represents a new family of neurotrophic factors with mechanisms of action fundamentally differentiated from its predecessors, and the potential to treat multiple diseases with a single biologic protein.

Publications of Note

- Research published in *Experimental Cell Research* [314(13): 2454-2467], described MANF to be a UPR upregulated protein that inhibits ER stress-induced cell death.
- Research published in *Molecular & Cellular Neuroscience* [39(3): 356-371] demonstrated that MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults.
- In research published in *The Journal of Neuroscience*, [29(30):9651–9659], MANF demonstrated neurorestorative properties in a rat model of Parkinson's and significant therapeutic potential for the treatment of Parkinson's Disease.
- MANF was shown to be an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart, according to peer-reviewed research published in *Circulation Research* [103: 1249-1258].
- Research published this past year in both *The Journal for Cerebral Blood Flow & Metabolism* [2010(30): 79-91] and *The Journal of Comparative Neurology* [515:116–124] suggests that MANF reduces ischemic brain injury and promotes behavioral recovery in rats, possibly through the inhibition of cell necrosis/apoptosis in the cerebral cortex.

Amarantus Therapeutics believes that AMRS001's profile in preventing ischemia-related injuries, coupled with its ubiquitous expression in major body organs and therapeutic benefit in treating several disease states in animal models, indicates that AMRS001 will become widely used to treat an array of apoptosis-associated disorders.

EVENTS CALENDAR

To request a meeting with an Amaranthus Therapeutics representative at one of the following events, please [contact us](#).

February 25, 2010 @ 1pm ET/10am PT

Partnering with Academic Research Facilities:
Access Innovation and Fill Dwindling Pipelines
Webinar hosted by MD Becker Partners

March 5, 2010

Boston Area
Road Show
Boston, MA

March 1-4, 2010

New York City
Road Show
New York, NY

March 4-6

American Society for NeuroTherapeutics
Hyatt Regency Bethesda
Bethesda, MD

March 2, 2010 @ 12:30pm ET

[Amarantus Therapeutics:](#)
[Analyst Luncheon](#)
Wilson Sonsini Goodrich & Rosati
New York, NY

March 16-17

WBT Showcase
Arlington Convention Center
Arlington, Texas

March 4, 2010

Private Equity 2010:
National Venture Capital & Growth Investment
Forum
The Yale Club New York
New York, NY

March 17, 2010

BayBio NEST: 7th Annual Life Sciences
Investor & Entrepreneur Roundtable
Sheraton Palo Alto Hotel
Palo Alto, CA

Corporate Contact

Amarantus Therapeutics, Inc
c/o The Parkinson's Institute
675 Almanor Ave
Sunnyvale, CA 94085
(p)408.737.2734
info@amarantustherapeutics.com
www.amarantustherapeutics.com